Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
| ▸ | MST1R | Q04912 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799128 | 0.91 | TRPV1 (0.61) | TRPV1MAPT | |
| SCHEMBL5802086 | 0.83 | ALDH1A1 (0.59) | TRPV1ALDH1A1METMST1RPOLB | |
| SCHEMBL5803079 | 0.79 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL2858127 | 0.78 | ALDH1A1 (0.74) | KDM4EALDH1A1NR1H4METMST1R | |
| SCHEMBL6338341 | 0.77 | ALDH1A1 (0.60) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL5226697 | 0.76 | TRPV1 (0.78) | TRPV1MAPTSMN1; SMN2 | |
| SCHEMBL30942703 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1NR1H4METMST1R | |
| SCHEMBL5799867 | 0.74 | TRPV1 (0.61) | TRPV1ALDH1A1MAPT | |
| SCHEMBL5126009 | 0.74 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL28693831 | 0.74 | ALDH1A1 (0.65) | KDM4EALDH1A1NR1H4METMST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | claimed |
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | AVPR1A, AVPR2, TRPV1 | TRPV1 3/4885KDM4E 3240/4885ALDH1A1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.